Australia markets closed

Imugene Limited (IMU.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1400-0.0050 (-3.45%)
At close: 04:10PM AEDT

Imugene Limited

4-6 Bligh Street
Suite 12.01 Level 12
Sydney, NSW 2000
Australia

https://www.imugene.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExec. Chairman350kN/A1956
Ms. Leslie ChongCEO, MD & Exec. Director1.07MN/AN/A
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.Chief Technology Officer422.98kN/AN/A
Dr. Monil Shah M.B.A., Pharm.D.Chief Bus. Officer821.74kN/AN/A
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDChief Financial OfficerN/AN/A1966
Ms. Ursula McCurrySr. VP of Clinical OperationsN/AN/AN/A
Dr. Giovanni SelvaggiChief Medical OfficerN/AN/AN/A
Mr. Nathan Jong C.A.Joint Company Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Corporate governance

Imugene Limited’s ISS governance QualityScore as of 28 January 2023 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.